Sarepta Therapeutics’ (SRPT) “Neutral” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $128.00 target price on the biotechnology company’s stock.

Several other equities analysts have also commented on SRPT. BMO Capital Markets started coverage on Sarepta Therapeutics in a research report on Wednesday, January 31st. They set an outperform rating and a $170.00 price objective on the stock. Wedbush reissued an outperform rating and set a $224.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Mizuho upped their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a buy rating in a research note on Wednesday, February 14th. TheStreet upgraded shares of Sarepta Therapeutics from a d rating to a c- rating in a research report on Monday, March 4th. Finally, Needham & Company LLC reissued a buy rating and issued a $166.00 price target on shares of Sarepta Therapeutics in a research note on Thursday. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of Moderate Buy and a consensus price target of $160.60.

Sarepta Therapeutics Price Performance

SRPT traded up $3.03 on Thursday, reaching $133.66. The company had a trading volume of 1,196,284 shares, compared to its average volume of 876,130. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $159.89. The company has a market cap of $12.63 billion, a price-to-earnings ratio of 1,215.09 and a beta of 0.95. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.45 and a current ratio of 4.05. The business has a 50 day simple moving average of $125.63 and a 200 day simple moving average of $110.81.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. The company had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm’s revenue was up 63.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.44) EPS. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post 2.14 EPS for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total value of $153,960.00. Following the completion of the sale, the chief financial officer now directly owns 39,114 shares in the company, valued at $5,018,326.20. The disclosure for this sale can be found here. Insiders sold 22,096 shares of company stock valued at $2,739,419 over the last quarter. 7.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Principal Securities Inc. purchased a new stake in Sarepta Therapeutics in the fourth quarter worth about $26,000. Mather Group LLC. bought a new position in Sarepta Therapeutics during the 1st quarter valued at approximately $28,000. Riggs Asset Managment Co. Inc. raised its stake in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the last quarter. Montag A & Associates Inc. purchased a new position in Sarepta Therapeutics during the third quarter valued at $30,000. Finally, Cary Street Partners Investment Advisory LLC boosted its holdings in Sarepta Therapeutics by 154.0% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 154 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.